The impact of disease severity on efficacy from a Phase 2b study of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)

被引：0

|

作者：

Kenney, C. ^{[1
]}

French, J. ^{[2
]}

Porter, R. ^{[3
]}

Perucca, E. ^{[4
]}

Brodie, M. ^{[5
]}

Rogawski, M. ^{[6
]}

Harden, C. ^{[1
]}

Rosenblut, C. Luzon ^{[1
]}

Qian, J. ^{[1
]}

Leung, J. ^{[1
]}

Beatch, G. ^{[1
]}

机构：

[1] Xenon Pharmaceut Inc, Burnaby, BC, Canada

[2] NYU, Langone Comprehens Epilepsy Ctr, New York, NY USA

[3] Univ Pennsylvania, Philadelphia, PA USA

[4] Monash Univ, Melbourne, Australia

[5] Univ Dept Med & Therapeut, Glasgow, Lanark, Scotland

[6] Univ Calif Davis, Sch Med, Davis, CA USA

来源：

EPILEPSIA | 2022年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

449

引用

收藏

页码：136 / 136

页数：1

相关论文

共 13 条

[11] Efficacy and Safety of XEN1101,aNovelPotassiumChannelOpener,in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial (vol 80, pg 1145, 2023)
不详
JAMA NEUROLOGY, 2024, 81 (02) : 200 - 200
[12] Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy
French, Jacqueline A.
Porter, Roger J.
Perucca, Emilio
Brodie, Martin J.
Rogawski, Michael A.
Harden, Cynthia
Qian, Jenny
Rosenblut, Constanza Luzon
Kenney, Christopher
Beatch, Gregory N.
X-TOLE Study Grp
EPILEPSIA OPEN, 2025,
[13] A First-In-Human Phase I Study to Assess the Pharmacodynamic Profile of a Novel Potassium Channel Opener (XEN1101) On Human Cortical Excitability with TMS-EEG and TMS-EMG
Premoli, I.
Beatch, G. N.
Rossini, P. G.
Abela, E.
Posadas, K.
Green, L.
Yogo, N.
Goldberg, P. Y.
Richardson, M. P.
EPILEPSIA, 2018, 59 : S51 - S52